A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe

Purpose: To compare the intraocular pressure (IOP) reducing effect and safety of fixed combination (FC) latanoprost/timolol with unfixed combination (UFC) brimonidine/timolol in patients with increased IOP. Methods: In this 6 month, randomised, evaluator masked, parallel group European study, patien...

Full description

Saved in:
Bibliographic Details
Published in:British journal of ophthalmology 2004-07, Vol.88 (7), p.877-883
Main Authors: García-Sánchez, J, Rouland, J-F, Spiegel, D, Pajic, B, Cunliffe, I, Traverso, C, Landry, J
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Brimonidine Tartrate
Clinical Science - Scientific Reports
Compliance
Drug dosages
Drug Therapy, Combination
Europe
Female
fixed combination
Glaucoma
Glaucoma - drug therapy
Glaucoma and intraocular pressure
Humans
Hypertension
intraocular pressure
Intraocular Pressure - drug effects
IOP
Latanoprost
Male
Medical sciences
Middle Aged
Ocular Hypertension - drug therapy
Ophthalmology
Prostaglandins F, Synthetic - adverse effects
Prostaglandins F, Synthetic - therapeutic use
Quinoxalines - adverse effects
Quinoxalines - therapeutic use
Timolol - adverse effects
Timolol - therapeutic use
Treatment Outcome
UFC
unfixed combination
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: To compare the intraocular pressure (IOP) reducing effect and safety of fixed combination (FC) latanoprost/timolol with unfixed combination (UFC) brimonidine/timolol in patients with increased IOP. Methods: In this 6 month, randomised, evaluator masked, parallel group European study, patients with glaucoma or ocular hypertension and IOP ≥21 mm Hg on monotherapy or >16 mm Hg on dual therapy received either FC latanoprost/timolol at 8:00AM or UFC brimonidine/timolol at 8:00AM and 8:00PM. The primary outcome was the difference from baseline to month 6 in mean diurnal IOP reduction. Results: 325 of 334 randomised patients were included in intent to treat analyses (FC latanoprost/timolol, 163; UFC brimonidine/timolol, 162). Baseline diurnal IOP levels were similar: FC latanoprost/timolol, 26.4 (SD 2.7) mm Hg; UFC brimonidine/timolol, 26.5 (SD 2.8) mm Hg (p = 0.851). At month 6, levels were 16.9 (SD 2.8) mm Hg in FC latanoprost/timolol patients and 18.2 (SD 3.1) mm Hg in UFC brimonidine/timolol patients (p
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.2003.029330